N/A Completed N=74

Lipids, Inflammation, and CV Risk in RA

Rheumatoid Arthritis · Cardiovascular Disease

Source: ClinicalTrials.gov NCT02714881 ↗

Enrolled (actual)

Serious AEs

2.7%

Results posted

Jan 2026

Primary outcomePrimary: Coronary Flow Reserve — 2.65 ratio

Summary

The objective of this study was to examine the relationship between inflammation, lipids, and cardiovascular risk in rheumatoid arthritis. The central hypothesis is that reducing inflammation will reduce cardiovascular risk as measured by coronary flow reserve. Additionally, we hypothesized that lipid levels may have a weaker correlation with CV risk compared to the general population.

Outcome Measures

Outcome	Result	p-value
PRIMARY Coronary Flow Reserve	2.65	—

Eligibility Criteria

Inclusion Criteria

RA diagnosed by a rheumatologist
Fulfills the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Criteria for RA
Age>35
Active RA as defined by treating rheumatologist
Biologic DMARD naive

Exclusion Criteria

Patients on statin or PCSK9 inhibitor therapy
Corticosteroid therapy >10mg prednisone or its equivalent as a maintenance treatment
Pregnancy
Unstable angina (chest pain) or shortness of breath
Severe valvular heart disease
Myocarditis
Pericarditis
Asthma with active wheezing
History of lymphoproliferative disease or melanoma (stage two or higher), active malignancy, or cancer treatment in the last 5 years
Active infectious disease (HIV, Tuberculosis, or Hepatitis B/C)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02714881). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.